TY - JOUR
T1 - Genetic variants of the BDNF and DRD3 genes in bipolar disorder comorbid with anxiety disorder
AU - Chang, Yun Hsuan
AU - Lee, Sheng Yu
AU - Chen, Shiou Lan
AU - Tzeng, Nian Sheng
AU - Wang, Tzu Yun
AU - Hui Lee, I.
AU - Chen, Po See
AU - Huang, San Yuan
AU - Kuang Yang, Yen
AU - Ko, Hui Chen
AU - Lu, Ru Band
N1 - Funding Information:
This study was supported by grant NHRI-EX99-9738NI from the Taiwan National Health Research Institute, NSC98-2627-B-006–017 and NSC99-2627-B-006–015 from the Taiwan National Science Council, and a grant from the National Cheng Kung University Project for Promoting Academic Excellence and Developing World Class Research Centers.
PY - 2013/12
Y1 - 2013/12
N2 - Background The high comorbidity rate between bipolar disorder (BP) and anxiety disorder (AD) has been studied in depth. This comorbidity is not as high in Han Chinese in Taiwan. Therefore, we explored the genetic effects BP comorbid with AD. Methods We recruited 1316 participants: 286 with BP-I, 681 with BP-II, and 349 healthy Controls. Genotypes of the BDNF Val66Met and DRD3 Ser9Gly polymorphisms were determined using polymerase chain reactions plus restriction fragment length polymorphism analysis. Results The DRD3 Ser9Gly polymorphism was associated with BP-II comorbid with AD (BPII+AD), and the BDNF Val66Met polymorphism was associated with BP-I comorbid with AD (BPI+AD). An interaction between the Val/Val genotype of the BDNF Val66Met and Gly/Gly polymorphism of the DRD3 Ser9Gly was found in BPII +AD, but not in BP-II not comorbid with AD (BPI-AD) compared with healthy Controls. Limitation The low comorbidity rate of AD in both BP subtypes, especially BP-I, limit generalizing our findings. Conclusion The involvement of the dopaminergic pathway in AD was confirmed, particularly with BP-II rather than BP-I. Because the Val/Val genotype of the BDNF Val66Met polymorphism, rather than the other two polymorphisms, has been associated with anxiety, it seems to affect BP-I comorbid with AD without the involvement of the DRD3 Seg9Gly polymorphism, but may modify the involvement of DRD3 Gly/Gly in BP-II comorbid with AD.
AB - Background The high comorbidity rate between bipolar disorder (BP) and anxiety disorder (AD) has been studied in depth. This comorbidity is not as high in Han Chinese in Taiwan. Therefore, we explored the genetic effects BP comorbid with AD. Methods We recruited 1316 participants: 286 with BP-I, 681 with BP-II, and 349 healthy Controls. Genotypes of the BDNF Val66Met and DRD3 Ser9Gly polymorphisms were determined using polymerase chain reactions plus restriction fragment length polymorphism analysis. Results The DRD3 Ser9Gly polymorphism was associated with BP-II comorbid with AD (BPII+AD), and the BDNF Val66Met polymorphism was associated with BP-I comorbid with AD (BPI+AD). An interaction between the Val/Val genotype of the BDNF Val66Met and Gly/Gly polymorphism of the DRD3 Ser9Gly was found in BPII +AD, but not in BP-II not comorbid with AD (BPI-AD) compared with healthy Controls. Limitation The low comorbidity rate of AD in both BP subtypes, especially BP-I, limit generalizing our findings. Conclusion The involvement of the dopaminergic pathway in AD was confirmed, particularly with BP-II rather than BP-I. Because the Val/Val genotype of the BDNF Val66Met polymorphism, rather than the other two polymorphisms, has been associated with anxiety, it seems to affect BP-I comorbid with AD without the involvement of the DRD3 Seg9Gly polymorphism, but may modify the involvement of DRD3 Gly/Gly in BP-II comorbid with AD.
UR - http://www.scopus.com/inward/record.url?scp=84886723982&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886723982&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2013.08.017
DO - 10.1016/j.jad.2013.08.017
M3 - Article
C2 - 24021960
AN - SCOPUS:84886723982
SN - 0165-0327
VL - 151
SP - 967
EP - 972
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
IS - 3
ER -